Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptide Hormones | 8 | 2022 | 76 | 2.360 |
Why?
|
| Adrenomedullin | 9 | 2022 | 105 | 2.310 |
Why?
|
| Calcitonin Gene-Related Peptide | 6 | 2021 | 162 | 1.580 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2022 | 199 | 1.510 |
Why?
|
| Uterine Artery | 2 | 2022 | 34 | 0.950 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 125 | 0.940 |
Why?
|
| Placenta | 3 | 2016 | 519 | 0.900 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2021 | 329 | 0.800 |
Why?
|
| Receptor Activity-Modifying Protein 3 | 3 | 2022 | 19 | 0.790 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 135 | 0.710 |
Why?
|
| Omentum | 3 | 2018 | 96 | 0.690 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2016 | 256 | 0.650 |
Why?
|
| Vasodilation | 2 | 2016 | 205 | 0.640 |
Why?
|
| Arteries | 2 | 2016 | 272 | 0.610 |
Why?
|
| Amniotic Fluid | 1 | 2016 | 121 | 0.540 |
Why?
|
| Mucin-1 | 1 | 2015 | 127 | 0.520 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 358 | 0.510 |
Why?
|
| Estrous Cycle | 1 | 2014 | 37 | 0.500 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 193 | 0.500 |
Why?
|
| Decidua | 1 | 2015 | 148 | 0.500 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 112 | 0.480 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 110 | 0.480 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 222 | 0.480 |
Why?
|
| Ovulation | 1 | 2014 | 107 | 0.470 |
Why?
|
| Neuropeptides | 1 | 2014 | 154 | 0.470 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 210 | 0.460 |
Why?
|
| Embryo Implantation | 1 | 2015 | 276 | 0.450 |
Why?
|
| Nitric Oxide | 2 | 2016 | 644 | 0.450 |
Why?
|
| Pregnancy | 10 | 2022 | 7549 | 0.430 |
Why?
|
| Receptor Activity-Modifying Protein 2 | 3 | 2022 | 15 | 0.380 |
Why?
|
| Ovary | 1 | 2014 | 668 | 0.370 |
Why?
|
| Peptide Fragments | 1 | 2016 | 1265 | 0.370 |
Why?
|
| Receptor Activity-Modifying Protein 1 | 2 | 2022 | 16 | 0.350 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2022 | 37 | 0.350 |
Why?
|
| Calcitonin Receptor-Like Protein | 3 | 2016 | 24 | 0.310 |
Why?
|
| Diabetes, Gestational | 2 | 2019 | 105 | 0.290 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 1615 | 0.280 |
Why?
|
| Trophoblasts | 2 | 2016 | 138 | 0.260 |
Why?
|
| Apamin | 1 | 2022 | 5 | 0.210 |
Why?
|
| Charybdotoxin | 1 | 2022 | 5 | 0.210 |
Why?
|
| Receptors, Calcitonin | 1 | 2022 | 26 | 0.210 |
Why?
|
| Dimerization | 1 | 2022 | 303 | 0.200 |
Why?
|
| Multigene Family | 1 | 2021 | 425 | 0.180 |
Why?
|
| Fetal Macrosomia | 1 | 2018 | 23 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 154 | 0.150 |
Why?
|
| Bradykinin | 1 | 2016 | 79 | 0.140 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 164 | 0.140 |
Why?
|
| Chorionic Villi | 1 | 2015 | 17 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2022 | 4945 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 249 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2018 | 235 | 0.130 |
Why?
|
| Mesenteric Arteries | 1 | 2015 | 55 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 267 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 127 | 0.130 |
Why?
|
| Female | 11 | 2022 | 142292 | 0.130 |
Why?
|
| Corpus Luteum | 1 | 2014 | 31 | 0.130 |
Why?
|
| Cyclic AMP | 1 | 2015 | 357 | 0.120 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2014 | 17 | 0.120 |
Why?
|
| Granulosa Cells | 1 | 2014 | 145 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2018 | 766 | 0.110 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 523 | 0.110 |
Why?
|
| Insulin | 1 | 2019 | 1446 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 447 | 0.110 |
Why?
|
| Fetal Development | 1 | 2014 | 119 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6130 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2022 | 2812 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 1540 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2073 | 0.090 |
Why?
|
| Rats | 2 | 2016 | 6107 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 2514 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5598 | 0.080 |
Why?
|
| Humans | 9 | 2022 | 262243 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6104 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 4026 | 0.060 |
Why?
|
| Animals | 3 | 2016 | 59487 | 0.050 |
Why?
|
| Receptors, Adrenomedullin | 1 | 2019 | 25 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 211 | 0.040 |
Why?
|
| Lipolysis | 1 | 2018 | 109 | 0.040 |
Why?
|
| Adult | 3 | 2019 | 78173 | 0.040 |
Why?
|
| Receptor Activity-Modifying Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 645 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 1139 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2019 | 1557 | 0.030 |
Why?
|
| Uterus | 1 | 2016 | 674 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 875 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5071 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 4808 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 14912 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 21735 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 11971 | 0.010 |
Why?
|